Benitec patents


Benitec’s primary focus in securing patent protection and adding value to its research programs is directed to technology improvements and composition of matter patents for products in development for a variety of therapeutic indications.  The portfolio is strategically structured to offer commercialisation opportunities for packaging platform technology patents with individual program specific patents.

The technology improvements patents include coverage of methods for selecting suitable hairpin RNA structures for optimally targeting multiple gene targets in a single ddRNAi construct (“Genetic Silencing”, “Double-stranded nucleic acid”), and selection of enhancers and promoters for designing ddRNAi constructs for enhanced expression and gene targeting in the liver (“RNAi expression constructs with liver-specific enhancer/promoter”, “Minigene expression cassette”)

The composition of matter filings being pursued by Benitec are aimed at protecting a combination of gene targets of interest in a range of therapeutic indications, as well as ddRNAi constructs directed to the specific gene targets.  The list of patents related to each of the programs is available below.

With filing dates commencing in 2005, these patents provide additional protection for Benitec’s programs to the platform technology patents licensed from CSIRO and Galapagos.  The current portfolio includes patent and patent applications for the hepatitis C, hepatitis B, age-related macular degeneration, lung cancer and pain programs, with an ongoing strategy to capture IP in new areas of interest and to seek continued protection for improvements related to existing programs.  The ongoing patenting strategy includes further composition of matter filings once lead candidates are identified for the individual programs.

 

Patent Title Patent No. Filing date Status Link to document
Genetic Silencing WO2001070949 16 March 2001 Granted
Singapore, South Africa, UK
Pending
Brazil
View
Double-stranded nucleic acid
WO2004106517
3 June 2004
Granted
Australia, New Zealand, Singapore, South Africa
View
Multiple promoter expression cassettes for simultaneous delivery of RNAi agents (Hepatitis C)
WO2005087926
4 March 2005
Granted
US (7727970, 8283461, 8691967), Australia, Canada, China, Europe, Israel, Japan, Korea
Pending
China, Europe
View
View
RNAi expression constructs (Hepatitis C)
WO2006084209
3 February 2006
Granted
US (7803611, 8076471), Australia, China, New Zealand
Pending
US, Europe, Canada, Hong Kong,
View
View
RNAi expression constructs with liver-specific enhancer/promoter (Hepatitis virus)
US 8,008,468 16 February 2006
Granted on 30 August 2011
View
Minigene expression cassette (Hepatitis)
WO2012055362
27 October 2011
Pending
Australia, Brazil, Canada, China, Hong Kong, Europe, India, Korea, Russia, US
View
Pain treatment
WO2013126963
28 February 2013
PCT filed
View
Age related macular degeneration treatment (AMD)
WO2014107763
8 January 2014
PCT filed
View